Summary Treatments to reduce fracture rates in adults with osteogenesis imperfecta are limited. Sclerostin antibody, developed for treating osteoporosis, has not been explored in adults with OI. This study demonstrates that treatment of adult OI mice respond favorably to sclerostin antibody therapy despite retention of the OI-causing defect. Introduction Osteogenesis imperfecta (OI) is a heritable collagen-related bone dysplasia, characterized by brittle bones with increased fracture risk. Although OI fracture risk is greatest before puberty, adults with OI remain at risk of fracture. Antiresorptive bisphosphonates are commonly used to treat adult OI, but have shown mixed efficacy. New treatments which consistently improve bone mass throughout the skeleton may improve patient outcomes. Neutralizing antibodies to sclerostin (Scl-Ab) are a novel anabolic therapy that have shown efficacy in preclinical studies by stimulating bone formation via the canonical wnt signaling pathway. The purpose of this study was to evaluate Scl-Ab in an adult 6 month old Brtl/+ model of OI that harbors a typical heterozygous OIcausing Gly>Cys substitution on Col1a1. Methods Six-month-old WT and Brtl/+ mice were treated with Scl-Ab (25 mg/kg, 2×/week) or Veh for 5 weeks. OCN and TRACP5b serum assays, dynamic histomorphometry, microCT and mechanical testing were performed. Results Adult Brtl/+ mice demonstrated a strong anabolic response to Scl-Ab with increased serum osteocalcin and bone formation rate. This anabolic response led to improved trabecular and cortical bone mass in the femur. Mechanical testing revealed Scl-Ab increased Brtl/+ femoral stiffness and strength. Conclusion Scl-Ab was successfully anabolic in an adult Brtl/+ model of OI.
Introduction
Osteogenesis imperfecta (OI) is a heritable disorder caused by mutations in type I collagen or collagen-associated proteins. Patients with OI have increased bone fragility, causing fracture susceptibility from minimal force, skeletal deformities, and growth deficiency [1] . OI is a disease that most severely affects children, and fracture rate tends to decrease after puberty. Despite this relative improvement, adults remain at an increased risk for fracture compared to a normal population, and commonly have osteoporotic BMD values [2] .
Treatment options to improve bone strength in adults with OI include antiresorptive bisphosphonates (BP) which are considered the current standard of care. However, the limited clinical trials investigating BP use in adult OI have found mixed reports, with some studies citing a reduced fracture incidence with treatment, while others show no therapeutic effect despite increases in bone mass [3] [4] [5] [6] . More effective therapies are needed for the treatment of adult OI and several preliminary reports have begun to investigate the use of anabolic teriparitide [7, 8] .
Neutralizing antibodies to sclerostin are a novel anabolic osteoporosis treatment strategy presently in clinical trials for the treatment of osteoporosis, and may be useful for increasing bone mass in adult OI. Sclerostin is a negative regulator of bone formation secreted primarily by osteocytes which inhibits anabolic canonical wnt signaling in osteoblasts by binding to the LRP4/5/6 complex [9] [10] [11] . Treatment with a neutralizing antibody to sclerostin (Scl-Ab) prevents sclerostin inhibition of canonical wnt signaling and effectively reduces sclerostin's ability to limit bone formation. Scl-Ab has been shown to be highly anabolic in preclinical models of osteoporosis and in phase 1 and phase 2 clinical trials of men and postmenopausal women [12] [13] [14] [15] .
The Brtl/+ mouse is a knock-in model for moderately severe Type IV OI with a G349C point mutation on Col1a1 that recreates an identical defect found in an OI patient [16] . The Brtl/+ mouse recapitulates multiple features of the observed clinical phenotype including short stature, reduced BMD, increased bone brittleness, and impaired remodeling [17] [18] [19] . Importantly, the Brtl/+ phenotype becomes less severe with age [17] , making it an appropriate model for testing the anabolic efficacy of Scl-Ab in adult OI.
We have previously reported that short-term Scl-Ab therapy is capable of stimulating bone formation and increasing bone mass in an 8 week old Brtl/+ model of OI [20] . Importantly, no preclinical studies have analyzed the effects of any anabolic or anti-catabolic agents in an adult model of OI. The purpose of this study was to determine if Scl-Ab could increase bone formation in osteoblasts harboring a classical OIcausing mutation to improve bone mass and whole bone strength in an adult Brtl/+ model of OI.
Materials and methods

Animals
Wildtype (WT) and Brtl/+ mice are maintained on a mixed background of Sv129/CD-1/C57BL/6S, and all Brtl/+ animals were the product of breeding male Brtl/+ with female WT. Six month old male WT and Brtl/+ mice were randomly assigned to Scl-Ab (Scl-Ab VI, Amgen, Thousand Oaks, CA) treatment or vehicle injection (PBS) with WT Veh n=8, WT Scl-Ab n= 9, Brtl/+ Veh n=8, and Brtl/+ Scl-Ab n=9. Sclerostin antibody was injected subcutaneously at 25 mg/kg, two times per week, for 5 weeks, following the protocol described previously [13] . To facilitate dynamic histomorphometry, calcein (30 mg/kg, i.p.) was injected at the start of experiment, 3 weeks before sac and 1 week before sac. Alizarin (30 mg/kg, i.p.) was injected 1 day prior to sacrifice. Body weights were recorded with each injection. Blood samples were collected at euthanasia by intracardiac puncture, serum separated by centrifuge, and stored at −80°C until analyzed by ELISA.
Left femurs were collected for microCT and mechanical testing, and right femurs for dynamic histomorphometry. Both were stored at −20°C in lactated ringers solution (LRS) soaked gauze until testing or further specimen preparation. All protocols and procedures involving animals were approved by the University of Michigan's Committee on Use and Care of Animals.
Serum assays
To measure osteoblast activity, serum osteocalcin (OCN) was quantified with a commercially available ELISA kit (BT-470, BTI, Stoughton, MA). To quantify osteoclast number, serum TRACP5b was measured with a commercially available solid phase immunofixed enzyme activity assay (MouseTRAP, IDS, Fountain Hills, AZ). Both serum tests were performed in duplicate.
MicroCT
Left femora were scanned in water using cone beam computed tomography (eXplore Locus SP, GE Healthcare Pre-Clinical Imaging, London, ON, Canada). Scan parameters included a 0.5°increment angle, four frames averaged, an 80 kVp and 80 μA X-ray source with a 0.508 mm Al filter to reduce beam hardening artifacts, and a beam flattener around the specimen holder [21] . All images were reconstructed and calibrated at 18 μm isotropic voxel size to a manufacturer supplied phantom of air, water and hydroxyapatite. The entire femora was reoriented with the mid-diaphysis parallel to the z-axis, and bone length was measured as the distance between the most proximal and distal transverse plans containing the femur. Regions of interest (ROI) were located for both cortical and trabecular parameters. A diaphyseal cortical ROI spanning 15 % of total femur length was located midway between the distal growth plate and third trochanter. Cortical bone was isolated with a fixed threshold of 2000 Hounsfield Units for all experimental groups. Parameters including cortical thickness, cross-sectional area, tissue mineral density (TMD), bending moment of inertia in the anterior-posterior direction (about the medial-lateral axis), endosteal perimeter, and periosteal perimeter were quantified with commercially available software (MicroView v2.2 Advanced Bone Analysis Application, GE Healthcare Pre-Clinical Imaging, London, ON, Canada). A trabecular ROI 10 % of total femur length was located approximately 100 μm proximal to the central, and most proximal, portion of the distal femoral growth plate. The inner cortical surface was defined with a splining algorithm. Due to the different morphology induced by Scl-Ab treatment, a fixed threshold could not be utilized without bias. Trabecular metaphyseal bone was isolated with a more conservative autothresholding algorithm for each specimen based on the bimodal distribution between marrow and bone [22] . Parameters including bone volume fraction (BV/TV), trabecular thickness (TbTh), and trabecular number (TbN) were quantified using standard stereology algorithms (MicroView v2.2). A 3D sphere fitting algorithm was also used to confirm the stereology data for TbTh [23] .
The eighth caudal vertebrae were dissected and scanned with the same protocol as the femora. Trabecular bone of the caudal vertebrae was analyzed in two ROIs, each spanning 9 % of bone length and placed adjacent to the proximal and distal growth plates. The trabecular surface was defined on the inner cortical surface with a splining algorithm. Cortical bone of the eighth caudal vertebrae was analyzed in a ROI spanning 9 % of bone length and placed in the middle of bone. Cortical thickness was measured along four lines originating at the center of gravity of the section, and placed 40 and 50°anterior to the medial-lateral plane similar to previous reports [24] .
Whole bone mechanical four-point bending Following μCT scanning, left femora were loaded to failure in four-point bending using a servohydraulic testing machine (MTS 858 MiniBionix, Eden Prarie, MN). All specimens were kept hydrated in LRS-soaked gauze until mechanical testing. In the same mid-diaphyseal region analyzed by μCT, the mid-diaphysis was loaded in four-point bending with the posterior surface oriented under tension. The distance between the wide, upper supports was 6.26 mm, and span between the narrow, lower supports 2.085 mm. The vertical displacement rate of the four-point bending apparatus in the anteriorposterior direction was 0.5 mm/s. Force was recorded by a 50 lb load cell (Sensotec) and vertical displacement by an external linear variable differential transducer (LVDT, Lucas Schavitts, Hampton, VA), both at 2000 Hz. A custom MATLAB script was used to calculate all parameters measured from the force-displacement data. Elastic energy was defined as the area under the load-displacement curve prior to the yield point, and plastic energy was defined as the area under the load-displacement curve from the yield point until failure. The yield point was defined as a 10 % reduction in secant stiffness relative to the initial tangent stiffness. Combining bending moment of inertia data from μCT with mechanical stiffness from four-point bending, the estimated elastic modulus was calculated using standard beam theory as previously described [17] .
Dynamic histomorphometry
Right femora were encased in epoxy (Kold Mount, VernonBenshoff, Albany, NY), and cut transversely with a low-speed saw (IsoMet, Beuhler, Lake Bluff, IL). The distal section of tissue was polished using progressive grades of silicon carbide abrasive paper (1,200, 2,400, and 4,000 grit) to a plane immediately distal to the third trochanter.
Fluorescent images were acquired using a Zeiss Axiovert 200M inverted microscope equipped with a structured illumination (Apotome) imaging system. This focuses the image on a specific plane, minimizes out-of-plane light, and negates the need for several micron thin sections. Multiple fluorescent images were taken with a 10× objective of the calcein (excitation: 485/20 nm, emission: 540/25 nm) and alizarin (excitation: 557/55 nm, emission: 615 nm) labels around the entire cortex. The 10× images of the cortex were merged into a single image (Photoshop, Adobe), and these merged images were analyzed using commercially available software (Bioquant Osteo v7.20.10, Nashville, TN). Bone surface (BS), mineral apposition rate (MAR), mineralizing surface to bone surface (MS/BS), and bone formation rate (BFR) were quantified on the calcein label given 3 weeks before sacrifice and the alizarin label given 1 day before sac on the periosteal surface and analyzed according to ASBMR standards [25] . In order to quantify the level of cortical drift in these mice and contrast the therapeutic response to prior studies analyzing rapidly growing 3-week old Brtl/+ mice treated with SclAb [26] , dynamic histomorphometry outcomes were also assessed in anatomic regions around the cortex with a method similar to Bivi et al. [27] . The fluorescent images were oriented anatomically by using the contralateral microCT femoral 3D images as a reference. The centroid of the fluorescent image was identified in ImageJ, and 110°angles from the centroid were used to define the anterior and posterior regions (Fig. 4) . MAR, MS/BS, and cortical thickness were quantified in each of these anterior and posterior subregions.
In any regions where there was no dual label, MAR was treated as a missing value. For the purpose of calculating BFR/ BS, a value of 0.1 μm/day was assigned to MAR where missing values were present. This value was determined from both looking at the biological limit observed in our specimens as well as values established in the literature [27] . BFR/BS was also analyzed when treated as a missing value. One animal (WT Veh) had a missing fluorescent label, most likely due to injection error, and was excluded from this analysis. Two additional animals (both WT Scl-Ab) displayed all fluorescent labels, but a portion of the endosteal surface had errors in image acquisition which could not be corrected. Both of these animals were excluded from analysis on the endosteal surface only. Final group sizes are shown in the relevant figures and tables.
Statistics
A two-factor multivariate ANOVA was performed for all data (IBM SPSS Statistics v21.0.0.0), the invididual factors as genotype (WT or Brtl/+) and treatment (Veh or Scl-Ab). The interaction term between genotype and treatment is also presented. Tukey's HSD post-hoc test was used to make comparisons except when unequal variances were observed. Dunnett's T3 post-hoc test was used for variables which displayed unequal variances. In all cases, p<0.05 was considered significant. Values between p=0.05 and p=0.10 are reported in all instances, and are referred to as "trends" in the text. All data are presented as mean±S.D.
Results
Body mass and bone length not changed by Scl-Ab
At the beginning of the experiment, WT animals (38.4±4.1 g) were significantly heavier than Brtl/+ (34.9±4.7 g) when pooling data from Veh and Scl-Ab groups for each genotype. Throughout the 5 weeks of experiment, WT Veh and Brtl/+ Veh did not have any significant changes in body mass. SclAb did not induce a change in body mass during the 5 weeks of treatment (not shown).
Brtl/+ Veh femurs were shorter than WT Veh as assessed by endpoint microCT (Table 1) . Scl-Ab had no effect on femoral length.
Scl-Ab increased serum osteocalcin and reduced serum TRACP5b
Scl-Ab significantly increased serum OCN levels in both WT (+49 %) and Brtl/+ (+47 %) indicative of increased bone formation and an anabolic response to therapy (Fig. 1) . Serum OCN levels were not different between Veh treated WT and Brtl/+ mice.
Serum TRACP5b, a marker of osteoclast number, was significantly decreased in WT (−78 %). Despite a numerical decrease in Brtl/+ (−66 %) with Scl-Ab treatment, it was not statistically significant (p=0.064) (Fig. 1) . The interaction term between genotype and treatment was not significant, suggesting that Scl-Ab did not have a differential effect on serum TRACP5b between WT and Brtl/+. Similar to OCN data, there were no phenotypic differences observed between WT Veh and Brtl/+Veh in serum TRACP5b.
Scl-Ab increases femoral trabecular thickness and trabecular number
Phenotypically, Brtl/+Veh animals had reduced femoral trabecular BV/TV (Fig. 2 ) compared to WT Veh (−93 %). These differences were the result of significant reductions in trabecular number (−67 %), but not trabecular thickness. In WT and Brtl/+, 5 weeks of Scl-Ab therapy significantly increased bone volume fraction (WT +117 %; Brtl +119 %) and trabecular BMD. The significant gains in femoral trabecular bone mass with therapy were a result of significant increases in both trabecular thickness (WT +38 %; Brtl + 29 %) and trabecular number (WT +70 %; Brtl +55 %).
Despite these significant gains in the femur, we observed no effect of Scl-Ab on trabecular bone of the 8th caudal vertebrae by microCT (Fig. 3) Scl-Ab increases Brtl/+ bone formation on endosteal and periosteal femora surfaces On the total periosteal surface of the diaphyseal femur, treatment of Brtl/+ with Scl-Ab significantly increased BFR/BS (+ 205 %) as a result of large increases in MAR (+132 %) and smaller gains in MS/BS (+38 %) (Fig. 4) . In WT animals, SclAb significantly increased MAR (+114 %) which led to an increase in BFR/BS (+169 %). Scl-Ab did not significantly increase MS/BS in WT on this surface even though seven of nine WT Scl-Ab animals had a MS/BS greater than the largest WT Veh value on the periosteal surface. The interaction term was not significant, suggesting Scl-Ab did not behave differently for periosteal MS/BS between genotypes. On the total endosteal surface of both genotypes, Scl-Ab significantly increased MS/BS (WT +181 %; Brtl +155 %) and MAR (WT +126 %; Brtl +180 %) to a similar extent. These gains led to large increases in endosteal BFR/BS in both genotypes with Scl-Ab treatment (WT +650 %; Brtl +683 %). No differences were found between WT Veh and Brtl Veh on either surface, but overall Brtl/+had greater endosteal MS/BS levels.
Regional analysis in the anterior and posterior regions of the cortex revealed a weak posterior shifting cortical drift pattern in both WT Veh and Brtl/+ Veh with more bone formation observed on the posterior periosteal surface compared to the anterior periosteal surface (Fig. 4a) . No complimentary cortical drift pattern was observed on the endosteal surface, where bone formation was very low in both genotypes.
Analyzing the effect of Scl-Ab on the anterior and posterior subregions revealed a similar effect on the periosteal surface in Fig. 1 Serum OCN is elevated in both WT and Brtl/+ with Scl-Ab. Serum TRACP5b is reduced with Scl-Ab therapy in WT and shows a trend (p= 0.064) toward reduced levels in Brtl/+, suggesting a decoupled effect on bone formation and bone resorption. *p<0.05 Scl-Ab vs. Veh Analyzing BFR/BS data as a missing value when no MAR was present led to an identical statistical conclusion on the periosteal and endosteal surfaces (data not shown). Two small statistical differences are apparent in the regional data on the low-forming endosteal posterior surface. Specifically, when BFR/BS is treated as a missing value, WT Veh vs WT Scl-Ab becomes significant on the endosteal posterior surface, and is no longer significant (p=0.068) for Brtl/+Veh vs Brtl/+Scl-Ab.
Scl-Ab increases Brtl/+ femoral cortical bone mass
Five weeks of Scl-Ab led to large increases in cortical crosssectional area (WT +36 %; Brtl +21 %) and cortical thickness (WT +42 %; Brtl +22 %) in both genotypes (Table 1) as measured by microCT of the left femora. Consistent with the stronger endosteal vs periosteal response observed by dynamic histomorphometry, Scl-Ab significantly decreased marrow area in both genotypes (WT −11 %; Brtl −19 %), although total area and bending moment of inertia were unchanged. A two-factor ANOVA revealed that overall Scl-Ab significantly increased the bending moment of inertia and TMD, although the Scl-Ab effects were not significant within each genotype for these outcomes.
No geometric phenotypic differences were observed between WT Veh and Brtl/+ Veh in the femoral cortex at this time point. However, overall genotype effects from a twofactor ANOVA revealed that relative to WT, Brtl/+had significantly reduced Marrow Area, significantly reduced Total Area, and significantly increased TMD.
Consistent with a lack of effect in caudal vertebral trabecular bone, there was no effect of Scl-Ab on cortical thickness in either WT or Brtl/+ 8th caudal vertebrae (Fig. 3) .
Brtl/+ whole bone mechanical properties improved by Scl-Ab Significant gains in whole bone mass with Scl-Ab led to significant improvements in whole bone mechanical properties as measured by mechanical four-point bending of the femoral mid-diaphysis (Fig. 5, Table 1 ). Specifically, 5 weeks of Scl-Ab caused large increases in Yield Load (WT +79 %; Brtl +77 %), Ultimate Load (WT +129 %; Brtl +127 %) and Bending Stiffness (WT +70 %; Brtl +38 %) in both genotypes (Table 1) . While increases in Energy to Failure with Scl-Ab treatment were expected based on the effects on Ultimate Load, the magnitude of the increases were unexpected (WT +526 %; Brtl +509 %). These observed increases in Energy to Failure with Scl-Ab were primarily a result of significantly increased plastic energy (WT +1498 %; Brtl + 1660 %) and in lesser part a result of increased elastic energy (WT +96 %; Brtl +153 %). The increased plastic energy with Fig. 3 MicroCT data from the 8th caudal vertebra demonstrate no effect of sclerostin antibody on trabecular (a-c) or cortical (d) bone structure in Brtl/+ or WT mice Anterior periosteal MAR: WT Veh n=7, WT Scl-Ab n=9, Brtl/+Veh n=7, Brtl/+Scl-Ab n=9
Anterior periosteal MS/BS, BFR/BS: WT Veh n=7, WT Scl-Ab n=9, Brtl/+Veh n=8, Brtl/+Scl-Ab n=9
Anterior endosteal MAR: WT Veh n=2, WT Scl-Ab n=7, Brtl/+Veh n=2, Brtl/+Scl-Ab n=9
Anterior endosteal MS/BS, BFR/BS: WT Veh n=7, WT Scl-Ab n=7, Brtl/+Veh n=8, Brtl/+Scl-Ab n=9
Posterior periosteal MAR. MS/BS, BFR/BS: WT Veh n=7, WT Scl-Ab n=9, Brtl/+Veh n=8, Brtl/+Scl-Ab n=9
Posterior endosteal MAR: WT Veh n=2, WT Scl-Ab n=4, Brtl/+Veh n=2, Brtl/+Scl-Ab n=9
Posterior endosteal MS/BS, BFR/BS: WT Veh n=7, WT Scl-Ab n=7, Brtl/+Veh n=8, Brtl/+Scl-Ab n=9 *p<0.05 Scl-Ab vs. Veh, no phenotypic differences were observed Similar to cortical microCT data, there was no significant whole bone mechanical property phenotype of Brtl/+ Veh vs WT Veh at this age. However, overall genotype effects from a two-factor ANOVA revealed that relative to WT, Brtl/+ had significantly reduced Energy to Failure, and significantly increased Elastic Modulus.
Discussion
In this study, we demonstrated that 5 weeks of Scl-Ab therapy was able to stimulate bone formation in an adult Brtl/+ mouse model of Type IV OI, leading to increased long bone mass and improved mechanical properties. No preclinical studies to date have analyzed the effect of pharmaceutical intervention for an adult mouse model of OI. In the context of existing anabolic and antiresorptive treatment options, Scl-Ab is a novel drug with strong therapeutic potential for adult OI patients. While current treatment options to improve bone strength in adults with OI focus on bisphosphonates (BP), the functional benefit of antiresorptive therapy appears modest. A randomized control trial of intravenous neridronate in adults with Type IV OI found increased BMD at the spine and hip with treatment as well as reduced total fracture incidence [4] . In a randomized placebo-controlled trial of oral alendronate in patients with Type I OI, increased BMD at the spine and hip was observed with treatment, but the study was not powered to detect fracture risk [3] . Two more recent clinical trials have noted similar increases in bone mass with BP treatment, but equivocal effects at reducing fractures in adults with OI [5, 6] . Moreover, BP efficacy may be dependent upon the type and severity of OI [5] as well as the dose. In light of these observations, strong motivation exists for the exploration of alternative therapies for the treatment of adult OI. To address this need, recent studies have begun to investigate the use of anabolic intermittent parathyroid hormone as a therapy for adult OI. An uncontrolled clinical trial indicates promising teriparatide efficacy in adult OI [7] , and a randomized doubleblind placebo-controlled trial also shows a benefit in Type I OI patients [8] .
Here, we noted suggestions of age-specific differences in response to Scl-Ab treatment, emphasizing the importance of examining adult OI mice separately from young OI mice. Rapidly growing 3 week Brtl/+ mice treated for 5 weeks with Scl-Ab showed a similar gain in femoral cortical bone area (WT +31 %; Brtl +25 %) when compared to the adult data (WT +36 %; Brtl +21 %). Furthermore, in the present study, we observed significant gains in femoral BV/TV in both WT and Brtl/+ with 5 weeks of Scl-Ab (Fig. 2 ). This contrasts with treatment of young Brtl/+ mice for an equivalent 5 weeks with Scl-Ab where we observed a more modest femoral trabecular response based on distance from the growth plate [28] . This data is suggestive of a differential trabecular response with age that may be related to differential turnover, altered sclerostin expression with growth, and perhaps the absence of confounding linear growth effects.
While we expected Scl-Ab to increase femoral BV/TV in adult WT and Brtl/+ mice in this study by increasing trabecular thickness, we did not expect to see large changes in trabecular number. Unexpectedly, we observed a large increase in trabecular number in the distal femoral metaphysis with 5 weeks of Scl-Ab (Fig. 2) . Decreased bone resorption could explain this finding by preserving trabeculae that might otherwise be lost to increased primary trabecular turnover. In this study, we found decreased serum TRACP5b with Scl-Ab, consistent with reports from others showing decreased bone resorption in humans [12] as well as preclinical rodent data [13] . Alternatively, the large differences in morphology induced by SclAb could affect quantification of trabecular number. If Veh animals contain trabeculae that were too thin to be detectable by microCT at the applied resolution, thickening of these structures to a detectable level by Scl-Ab could result in the increased trabecular number observed. While our conservative specimen-specific thresholding method helps guard against these effects, it does not eliminate them.
Interestingly, we observed no effect of Scl-Ab on either the trabecular bone or cortical thickness of the 8th caudal vertebrae in this study. One previous study in adult female rats has observed an anabolic response with Scl-Ab in the caudal vertebrae [29] . Specifically, increases in BFR/BS and BV/ TV were measured in sections by histomorphometry at this site of yellow marrow. Interestingly, other studies of anabolic PTH have found reduced effects in the caudal vertebrae relative to the distal femur or lumbar vertebrae in ovariectomized rats with doses 20 % of the present study [30] . Additional studies have observed a robust response to anabolic PTH in caudal vertebrae [31] while others have suggested that an anabolic PTH response in caudal vertebrae may be supported by mechanical loading [32] . Our lack of difference in BV/TV may reflect differences in local sclerostin expression or drug delivery in the caudal vertebrae, as differences in the mouse compared to the rat, or dose of Scl-Ab.
The femoral cortical dynamic histomorphometry response to Scl-Ab was also qualitatively different between the adult mice analyzed in this study and our treatment of rapidly growing 3 weeks Brtl/+ mice. In the present study, Scl-Ab was able to consistently increase MAR on the periosteal surface. On the endosteal surface, where lower levels of bone formation were found in control animals, Scl-Ab was able to increase both MS/BS and MAR in most cases. Previously, we reported that a short-term 2 week Scl-Ab therapy in 8 week old Brtl/+ mice stimulated femoral periosteal BFR by increasing mineralizing surface, but not mineral apposition rate [20] . In addition, we have also treated rapidly growing 3-week-old Brtl/+ mice for 5 weeks with Scl-Ab and similarly found that Scl-Ab was able to increase bone formation by primarily increasing MS/BS, with no effect on MAR on both the endosteal and periosteal surfaces [26] . Although the cortical drift pattern we observed was weak in these 6-month-old mice, the posterior periosteal surface remained a location of high bone formation (MS/BS) similar to our observation in rapidly growing 3-week-old mice. The regional dynamic histomorphometry analysis allows us to conclude that Scl-Ab can increase MAR in regions that have high MS/BS in adult animals, but is unable to increase MAR in these regions in rapidly growing animals. These findings may be related to different sclerostin expression levels with age, and a strong underlying cortical drift pattern in growing mice. In addition, rapidly growing 3 week old mice have a high Veh MAR (∼1.25-2.5 μm/day) and may be operating at near maximum output, leaving little room for further stimulation via Scl-Ab. In contrast, lower Veh MAR levels in adult 6 months (∼0.3 μm/day) leave room for Scl-Ab to have a potent effect, and may explain the age-dependent effect of Scl-Ab on MAR.
Increased tissue brittleness is a hallmark feature of the OI phenotype. The Brtl/+ model demonstrates increased brittleness at young ages when mechanically tested to failure, and remains brittle through 6 months [17] . In this study, we observed that mid-diaphyseal cortical bone of the Brtl/+ femur had increased TMD, decreased energy to failure, and increased elastic modulus. Previously, we found an unexpected result that a short-term treatment with Scl-Ab significantly increased Post-Yield Displacement (indicating decreased tissue brittleness) in WT animals, but not Brtl/+ [20] . In the present study, we found exceptionally large gains in PYD with 5 weeks of Scl-Ab treatment in both WT and Brtl/+. While we remain aware of the numerous violations of beam theory assumptions and loading differences that may result from Scl-Ab induced geometrical differences, the magnitude of the changes in PYD (WT +539 %; Brtl +541 %) is difficult to ignore. The cause of this difference could be related to the addition of new, more ductile bone, to a mature skeleton. Alternatively, it could reflect that bone formed under the influence of Scl-Ab may be of a different material independent of tissue age. It will be important to determine if these reductions in brittleness are persistent changes, or transient changes that disappear quickly after cessation of therapy. While the beneficial materials differences of Scl-Ab on PYD are suggestive, these data require corroboration with detailed composition and mechanical techniques. Interestingly, we observed an increase in the estimated elastic modulus with Scl-Ab in WT, but not Brtl/+. This finding was not accompanied by similar gains in WT tissue mineral density, suggesting that changes at a level of organization below that of overall cortical size, but larger than tissue ultrastructural characteristics may be at play. Alternatively, the robust changes in cortical thickness found with sclerostin antibody may induce additional artifact related to beam theory calculations, as has been previously described [33] .
There are several limitations of this study. First, osteogenesis imperfecta is a heterogeneous disease with a wide range of phenotypes caused by many different mutations. In this study, we used a mouse model harboring a mutation found in a patient with moderately severe Type IV OI. The findings of this study in the Brtl/+ mouse may not apply to all mutations and types of OI, including recessive forms as well as those with null collagen alleles. In addition, while Scl-Ab was potently anabolic in adult Brtl/+ mice in this study, it is unclear how long these gains will persist after cessation of therapy. The Scl-Ab dose chosen for these studies was consistent with prior preclinical ovariecto my studies modeling postmenopausal osteoporosis [15] . As drug pharmokinetics can vary greatly between human vs. rodent, the human "equivalent" dose is not known, but we recognize that the 25 mg/kg twice per week dose is likely higher than the currently proposed doses for humans.
In summary, we have demonstrated that 5 weeks of Scl-Ab therapy was capable of increasing bone formation in an adult model of OI with a classic Gly>Cys substitution in col1a1. OI is a disease that most severely affects children, and fracture rate tends to decrease after puberty. Despite this relative improvement, adults remain at an increased risk for fracture compared to a normal population, and commonly have osteoporotic BMD values. While bisphosphonate therapy is often used in adult OI patients, there is a need for more effective anabolic therapeutics to improve patient outcomes. Scl-Ab is a unique and promising anabolic therapy which may be particularly useful for the treatment of adult OI by stimulating bone formation, adding bone mass, and increasing bone strength.
